

Interventional Series – MedIntelliBase™ #001-05

“Coronary Artery Revascularization: Developments and Trends in Restenosis Prevention and Treatment”

INDEX

Note: With this new MedIntelliBase e-Report series, The Next Phase SMARt Chart®, Clinical Trials, and Competing Companies databases have been integrated into the outline of this SMARt Volumes™ Core e-Report Index. (Full report is ~700 pages.)

VOLUME 1. METHODOLOGY & HOW TO USE (8 pages)

<i>1.1</i>	<i>MedIntelliBase Research Methodology</i>	<i>1-1</i>
<i>1.2</i>	<i>How to Use this MedIntelliBase e-Report.....</i>	<i>1-5</i>
<i>1.2.1</i>	<i>The Next Phase SMARt Chart® Database of Competing Technologies</i>	<i>1-6</i>
<i>1.2.2</i>	<i>The Clinical Trials Database.....</i>	<i>1-7</i>
<i>1.2.3</i>	<i>The SMARt Volumes™ Core.....</i>	<i>1-7</i>
<i>1.3</i>	<i>Online Access</i>	<i>1-8</i>

VOLUME 2. TODAY, TOMORROW & FUTURE SOLUTIONS [EXECUTIVE SUMMARY] (31 pages)

<i>2.1</i>	<i>Market Overview</i>	<i>2-1</i>
<i>2.2</i>	<i>Coronary Artery Disease.....</i>	<i>2-1</i>
<i>2.3</i>	<i>Criteria for Revascularization Therapies.....</i>	<i>2-2</i>
<i>2.4</i>	<i>Today – Drug-Eluting Stents.....</i>	<i>2-4</i>

2.4.1	Market Size and Dynamics Today	2-6
2.4.2	Market Window of Opportunity for Each Major Therapy.....	2-11
2.5	<i>Tomorrow – Advances in Stenting</i>	2-12
2.5.1	Novel Stent Designs.....	2-13
2.5.2	Bioabsorbable Stent Systems	2-13
2.5.3	Pro-Healing Concepts	2-15
2.5.4	The Market Dynamics Tomorrow	2-16
2.6	<i>Future Solutions.....</i>	2-20
2.6.1	Gene Therapy	2-20
2.6.2	Protein Therapy.....	2-21
2.6.3	Angiogenesis and Arteriogenesis.....	2-21
2.6.4	Restenosis Prevention via Diagnostic Patient Screening.....	2-22
2.6.5	Other Advanced Therapies	2-23
2.6.6	The Market Dynamics in the Future	2-24
2.7	<i>Conclusions on Today, Tomorrow, and Future Solutions</i>	2-28

VOLUME 3. MARKET OVERVIEW (27 pages)

3.1	<i>Market Situation for Revascularization</i>	3-1
3.2	<i>Revascularization Market Potential and Patient Demographics.....</i>	3-7
3.3	<i>Market Impact of Stents</i>	3-9
3.3.1	Bare Metal Stents	3-9
3.3.2	Coated Stents	3-14
3.3.3	Drug-Eluting Stents	3-15
3.4	<i>Market Exit by Brachytherapy.....</i>	3-16
3.5	<i>Other Current Market Trends</i>	3-18
3.5.1	Shifting Usage Rates of Therapies.....	3-18
3.5.2	Integration of Medical Specialties	3-19
3.6	<i>Projected Market Trends</i>	3-20

3.7	<i>Trends Behind PCI Procedure Volumes</i>	3-21
3.7.1	Global PCI Procedure Volumes.....	3-22
3.8	<i>Strategic Alliances</i>	3-22
3.9	<i>Next Generation Technologies</i>	3-25

VOLUME 4. RESTENOSIS AND REVASCULARIZATION **MOLECULAR BIOLOGY AND PHYSIOLOGY (11 pages)**

4.1	<i>Defining the Types of Restenosis and Revascularization</i>	4-1
4.2	<i>Structure of the Arterial Wall</i>	4-2
4.3	<i>New Theories on the Molecular Biology of Restenosis</i>	4-5
4.3.1	Preclinical & Clinical Research Design Considerations for Anti- Restenosis Therapies.....	4-5
4.3.1.1	Arterial Vessel Wall Injury Model in Animal Studies.....	4-5
4.3.1.2	The Arterial Vessel Wall Injury Model in Human Studies.....	4-7
4.3.1.3	Cell Apoptosis, “Programmed Cell Death”	4-7
4.4	<i>Cytomegalovirus Infection</i>	4-9
4.5	<i>Comparing Physiology of Coronary vs. Peripheral Arteries</i>	4-10
4.5.1	Unique Features of the Arterial Walls	4-10
4.5.2	Impact of Differing Responses to Restenosis and Revascularization...4-11	

VOLUME 5. CLINICAL ISSUES IN RESTENOSIS AND **REVASCULARIZATION (16 pages)**

5.1	<i>Clinical Definitions of Restenosis and Revascularization</i>	5-1
5.2	<i>Lesion Classification Systems</i>	5-1
5.2.1	Yesterday’s Lesion Classifications for PTCA Procedures	5-3
5.2.2	Today’s Lesion Classifications – Based on all PCI Procedures	5-5

5.3 Clinical Issues in Restenosis..... 5-6

5.3.1 Risk Factors for Restenosis.....5-6

 5.3.1.1 Angioplasty Patients’ Risk of Restenosis5-6

 5.3.1.2 Stent Patients’ Risk of In-Stent Restenosis.....5-7

 5.3.1.3 Types of In-Stent Restenosis.....5-8

 5.3.1.4 CMV.....5-9

5.4 Weighing the Relative Cost-Effectiveness of Therapies..... 5-10

5.4.1 Stents vs. CABG5-10

5.4.2 DES vs. BMS Pricing Issues.....5-12

 5.4.2.1 Hospital Costs – A Critical DES versus BMS Issue5-12

 5.4.2.2 Overall Procedural Costs – Another Critical DES versus BMS Issue.....5-13

5.5 New Multidisciplinary Interventionalist 5-16

VOLUME 6. CLINICAL TRIALS DATABASE

VOLUME 7. ANALYSIS OF COMPETING TECHNOLOGIES (119 pages)

7.1 Essential Criteria for Superior Interventional Therapies.... 7-2

7.2 Variability in Incidence of Restenosis by Artery Bed 7-4

7.3 Diagnostic Testing for Restenosis 7-4

7.4 Overview - Interventional Therapies Discussed in this Volume..... 7-5

7.5 Medical Therapies 7-5

 7.5.1 Systemic Drug Delivery..... 7-6

7.5.1.1	<i>Advantages and Disadvantages of Systemic Drug Delivery</i>	7-7
7.5.1.2	<i>Therapeutic Targets of Drugs Delivered Systemically</i>	7-9
7.5.1.3	<i>Systemically Delivered Drugs</i>	7-11
7.5.1.3.1	ACE Inhibitors and Angiotensin II Antagonists	7-11
7.5.1.3.2	Antiproliferative Growth Factor Inhibitors	7-12
7.5.1.3.2.1	Tranilast	7-13
7.5.1.3.2.2	Trapidil.....	7-14
7.5.1.3.3	Statins and Lipid-Lowering Agents	7-15
7.5.1.3.3.1	Pravastatin.....	7-16
7.5.1.3.3.2	Probucol, an antioxidant	7-17
7.5.1.3.4	Fish Oils and Fatty Acids	7-19
7.5.1.3.5	Anticoagulants	7-20
7.5.1.3.6	Anti-Platelet Agents	7-20
7.5.1.3.6.1	Aspirin.....	7-20
7.5.1.3.6.2	Aspirin Combined with Other Drugs	7-21
7.5.1.3.7	Platelet Aggregation Inhibitors	7-21
7.5.1.3.7.1	New Anti-Platelet Drugs.....	7-21
7.5.1.3.7.2	Cilostazol	7-22
7.5.1.3.8	GP IIb/IIIa Inhibitors.....	7-24
7.5.1.3.8.1	Intravenous GP IIb/IIIa Inhibitors	7-24
7.5.1.3.8.2	Ticlopidine and Clopidogrel	7-25
7.5.1.4	<i>Limitations of Systemic Drug Delivery</i>	7-26
7.5.1.5	<i>Trends in Systemic Drug Therapy</i>	7-26
7.5.2	Local Drug Delivery	7-27
7.5.2.1	<i>Locally Delivered Drugs</i>	7-29
7.5.2.1.1	Anticoagulants	7-31
7.5.2.1.1.1	Heparin for Local Drug Delivery via Catheter	7-31
7.5.2.2	<i>Trends in Locally Delivered Drugs</i>	7-31
7.5.2.3	<i>Advantages & Limitations of Local Drug Delivery</i>	7-32
7.5.3	Concluding Discussion on Medical Therapies	7-34

7.6	Medical Devices & Systems	7-35
7.6.1	Local Drug Delivery Devices	7-35
7.6.1.1	<i>Intravascular – Mechanism of Local Drug Delivery</i>	7-36
7.6.1.1.1	Coated Guidewires	7-37
7.6.1.1.2	Local Drug Delivery Catheters.....	7-37
7.6.1.1.3	Coated Stents	7-41
7.6.1.1.4	Advanced Angioplasty Dilation Catheters Stents	7-43
7.6.1.1.4.1	Cutting Balloons	7-43
7.6.1.1.4.2	“Scoring” Balloons.....	7-44
7.6.2	Atherectomy.....	7-45
7.6.2.1	<i>Rotational Atherectomy</i>	7-45
7.6.2.2	<i>Directional Coronary Atherectomy</i>	7-46
7.6.2.3	<i>Extractional Atherectomy</i>	7-46
7.6.3	Stents.....	7-47
7.6.3.1	<i>Bare Metal Stents</i>	7-48
7.6.3.2	<i>Biodegradable Stents</i>	7-50
7.6.3.3	<i>Coated Stents</i>	7-51
7.6.3.3.1	Inert Coated Stents	7-52
7.6.3.3.1.1	Phosphorylcholine (PC) Coated Stents.....	7-52
7.6.3.3.1.2	Carbon Coated Stents.....	7-54
7.6.3.3.1.3	ePTFE Stent Grafts	7-55
7.6.3.3.2	Drug-coated Stents	7-55
7.6.3.3.2.1	Heparin Coated Stents.....	7-55
7.6.3.3.2.2	ReoPro® (abciximab) Coated Stents	7-58
7.6.3.3.3	Antiproliferative Drug-Eluting Stents	7-58
7.6.3.3.3.1	The Cypher™ Sirolimus-Eluting BX Velocity Coronary Artery Stent.....	7-58
7.6.3.3.3.2	Paclitaxel Coated Stents, an Introduction	7-65
7.6.3.3.3.3	The Logic PTX™ Paclitaxel-Eluting Coronary Artery Stent.....	7-66
7.6.3.3.3.4	The Achieve™ Paclitaxel-Eluting Coronary Artery Stent.....	7-66

7.6.3.3.3.5	Taxus Express™ Paclitaxel-Eluting Coronary Artery Stent.....	7-67
7.6.3.3.3.6	Pharma-Link™ Coated Stent Program.....	7-69
7.6.3.3.3.7	Resten-NG Antisense-Eluting Coronary Stent from Medtronic.....	7-69
7.6.3.3.3.8	Tacrolimus-Coated Coronary Artery Stent.....	7-70
7.6.3.3.3.9	Abbott Laboratories / Biodiv Ysio Drug-Eluting Coronary Stents.....	7-70
7.6.3.3.3.10	Conclusion on Drug-Eluting Stents.....	7-71
7.6.3.3.4	Pro-Healing Stents.....	7-72
7.6.3.4	<i>Implications for Restenosis in Direct Stenting</i>	7-73
7.6.4	Brachytherapy.....	7-75
7.6.4.1	<i>Gamma Emitters</i>	7-76
7.6.4.2	<i>Beta Emitters</i>	7-77
7.6.4.3	<i>Issues of Brachytherapy</i>	7-77
7.6.4.4	<i>Pellet-form Seed Train System</i>	7-78
7.6.4.5	<i>Wire Delivery Systems</i>	7-80
7.6.4.6	<i>Balloon Catheter Delivery Systems</i>	7-82
7.6.4.7	<i>Radiation Coated Stents</i>	7-83
7.6.4.8	<i>Conclusion on Brachytherapy</i>	7-83
7.6.5	Other Medical Devices and Systems.....	7-84
7.6.5.1	<i>Energy-enabled Drug Delivery Systems</i>	7-85
7.6.5.1.1	Electrical Fields and Electrical Conduction.....	7-85
7.6.5.1.2	Ultrasound for Local Drug Delivery.....	7-86
7.6.5.1.3	Ultrasound as a Standalone Therapy for Restenosis.....	7-86
7.6.5.1.3.1	Angiosonics, Vascular Solutions.....	7-87
7.6.5.1.3.2	PharmaSonics.....	7-87
7.6.5.1.4	Photodynamic Therapy.....	7-88
7.6.5.1.5	Thermal Angioplasty.....	7-92
7.6.5.1.6	Cryogenic Angioplasty.....	7-92
7.7	Gene Therapy.....	7-92
7.7.1	Gene Vector Technology.....	7-95
7.7.2	Gene Therapy Modalities.....	7-97

7.7.2.1	<i>Recombinant DNA</i>	7-97
7.7.2.1.1	Transgene-VasoSten TIMP-4 Gene	7-97
7.7.2.1.2	P27/P16 Cell-Cycle Inhibitors.....	7-99
7.7.2.1.2.1	AV-W9 Fusion Gene	7-99
7.7.2.1.2.2	Genzyme Corporation's Restenosis Program	7-100
7.7.2.1.3	E2F Decoy Gene	7-100
7.7.2.2	<i>Nitric Oxide (NO) Synthesis</i>	7-101
7.7.2.3	<i>Antisense Oligonucleotides</i>	7-102
7.7.2.3.1	AVI Biopharma's Resten NG™ Antisense Compound	7-104
7.7.2.3.2	Lynx Therapeutics' LR-3280 Antisense Compound	7-106
7.7.2.4	<i>The Ribozyme Strategy</i>	7-106
7.7.2.4.1	RestenASE™ for Coronary Restenosis and Coronary In-stent Restenosis.....	7-106
7.7.2.4.2	Anti-TGF-β Ribozyme in a Preclinical Model.....	7-107
7.7.3	Other Novel Gene Therapy Approaches.....	7-107
7.7.3.1	<i>Radiopharmaceuticals</i>	7-107
7.7.4	Trends in Gene Therapy for Restenosis.....	7-108
7.7.5	Angiogenesis.....	7-109
7.8	Other Advanced Therapies	7-110
7.8.1	Advanced Agents	7-110
7.8.1.1	<i>Antibodies</i>	7-111
7.8.1.2	<i>Cytochalasin B</i>	7-111
7.8.1.3	<i>Chitan / Chitosan</i>	7-111
7.8.1.4	<i>NO (Nitric Oxide) Based Therapies</i>	7-112
7.8.1.4.1	NitroMed's NitRx™ Technology	7-112
7.8.1.4.2	Titanium NO-Coated Stents	7-113
7.8.1.4.3	ENOS and INOS	7-114
7.8.1.5	<i>Angiogenic Growth Factors</i>	7-114
7.8.1.5.1	Vascular Endothelial Growth Factor (VEGF).....	7-114
7.8.1.5.2	Other Growth Factors.....	7-116

7.8.1.6	<i>Sulfated Cyclodextrins</i>	7-116
7.8.2	Advanced Agents and Local Delivery Systems.....	7-116
7.8.3	Other Advanced Therapies in Conclusion	7-117

VOLUME 8 THE NEXT PHASE SMART CHART® DATABASE

VOLUME 9 GLOSSARY OF TERMS **9-1**

VOLUME 10. COMPETING COMPANIES DATABASE

CUSTOMER INFORMATION

LIST OF FIGURES

<i>Figure 2-1: Worldwide, U.S., and OUS PCI Procedure Volume & Patient Population, 2005 Estimates</i>	2-7
<i>Figure 2-2: Reported Restenosis Rates for Selected Commercial Therapies as of 2005</i>	2-8
<i>Figure 2-3: Worldwide and U.S. PCI and Stent Market: Procedure Volumes & Percentages of PCI Procedures using Stents – Five Year Estimates, 2001 to 2005</i>	2-9
<i>Figure 2-4: PCI Modalities – Estimated U.S. Procedure Volumes, 2001 to 2005</i>	2-10
<i>Figure 2-5: BMS Versus DES – Estimated U.S. Procedure Volumes, 2001 to 2005.</i>	2-11
<i>Figure 2-6: Selected Revascularization Therapies – Projected U.S. Market Window, Early 1980s-2040+</i>	2-12
<i>Figure 2-7: Worldwide, U.S., and OUS PCI Market Potential – Three Year Projection, 2006 to 2008</i>	2-17
<i>Figure 2-8: PCI Modalities – Estimated U.S. Procedure Volumes, 2001 to 2008</i>	2-18

Figure 2-9: BMS vs. DES – Estimated U.S. Procedure Volumes, 2001 to 2008	2-19
Figure 2-10: Worldwide, U.S., and OUS PCI Market Potential – Long-term Projections, 2005 to 2030.....	2-24
Figure 2-11: Worldwide, U.S., and OUS PCI Procedure Volumes – 2005, 2010, 2020, & 2030 Estimates	2-26
Figure 2-12: Advanced Restenosis Therapies – Specific Modalities & Companies	2-29
Figure 3-1: Commercial Therapies – Device Descriptions and Restenosis Rates	3-3
Figure 3-2: Reported Restenosis Rates for Commercial and In-Development Therapies, 2005	3-5
Figure 3-3: Revascularization Therapies – Projected U.S. Market Window, 1980-2040+.....	3-6
Figure 3-4: Worldwide, U.S., and OUS PCI Market Potential – Ten Year Projection, 2001 to 2010	3-8
Figure 3-5: Worldwide, U.S., and OUS PCI Procedure Volume & Patient Population, 2005 Estimates.....	3-9
Figure 3-6: Worldwide and U.S. Stent Market Potential: Procedure Volumes & Percentage of PCI Procedures using Stents – Ten Year Projection, 2001 to 2010	3-11
Figure 3-7: U.S. Stent Procedures as a Percentage of Standard PCI Procedures – Estimated Volumes, 2001 to 2010.....	3-12
Figure 3-8: BMS vs. DES – Estimated U.S. Procedure Volumes, 2001 to 2010	3-16
Figure 3-9: PCI Modalities – Estimated U.S. Procedure Volumes, 2001 to 2010	3-19
Figure 3-10: U.S. PCI Procedures vs. Worldwide PCI Procedures – Estimated Volumes and Percentages, 2001 to 2010.....	3-23
Figure 4-1: Illustration: Layers and Sub-Layers of an Arterial Vessel Wall.....	4-3
Figure 4-2: Histogram: Layers of an Arterial Vessel Wall.....	4-4
Figure 5-1: Mechanisms of Inflammation Before and After PCI.....	5-2
Figure 5-2: 1993 ACC/AHA PTCA Guidelines Lesion Classification System.....	5-4
Figure 5-3: 2001 ACC/AHA PCI Guidelines Lesion Classification System	5-5
Figure 7-1: Advantages and Disadvantages of Systemic Drug Delivery for the Prevention and Treatment of Restenosis.....	7-8

Figure 7-2: Systemic Drugs and Their Therapeutic Targets	7-10
Figure 7-3: Clinical Trials with Probucol Showing a Decrease in Restenosis Rates	7-19
Figure 7-4: Clinical Trials with Cilostazol Showing a Decrease in Restenosis Rates or Late Loss.....	7-23
Figure 7-5: Locally Deliverable Drugs and Their Therapeutic Targets	7-30
Figure 7-6: Advantages and Disadvantages of Local Drug Delivery for the Prevention and Treatment of Restenosis.....	7-34
Figure 7-7: Catheter-Based Drug Delivery Systems – Function & Status.....	7-39
Figure 7-8: Antiproliferative Drug-Eluting Stents – Commercial & in Development.....	7-60
Figure 7-9: Brachytherapy Delivery Systems	7-79
Figure 7-10: Photosensitizers – Active Preclinical and Clinical Trials.....	7-90
Figure 7-11: Summary of Genetic Targets and Agents under Development to Prevent Restenosis	7-94
Figure 7-12: Common Vectors Used in Developing Gene Therapy for Restenosis	7-98